Baumeister, Julian
Maié, Tiago
Chatain, Nicolas
Gan, Lin
Weinbergerova, Barbora
de Toledo, Marcelo A. S.
Eschweiler, Jörg
Maurer, Angela
Mayer, Jiri
Kubesova, Blanka
Racil, Zdenek
Schuppert, Andreas
Costa, Ivan
Koschmieder, Steffen
Brümmendorf, Tim H.
Gezer, Deniz
Funding for this research was provided by:
deutsche forschungsgemeinschaft (KO2155/6-1, BR1782/5-1, KO2155/7-1, GE2811/4-1)
interdisziplinäres zentrum für klinische forschung, universitätsklinikum würzburg (grant O1-6, grant O1-6)
ministerstvo zdravotnictví ceské republiky (00023736, 65269705)
Universitätsklinikum RWTH Aachen
Article History
Received: 22 June 2021
Accepted: 11 July 2021
First Online: 14 August 2021
Declarations
:
: PB and BM samples from MPN patients were obtained at the Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation at Uniklinik RWTH Aachen after written informed consent and approval of the local ethics committee (EK127/12). Unfractionated BM samples from JAK2V617F-positive untreated MPN patients within the CELL project — MPN database (MIND) — after written informed consent were provided from the Department of Internal Medicine, Hematology and Oncology of Brno University Hospital, Czech Republic. Femoral heads were obtained from the Department of Orthopedics from the Uniklinik RWTH Aachen, each after written informed consent and in compliance with the local ethics committee (EK300/13).
: See “Ethics approval.”
: The patients’ written informed consent includes a statement that their data will be published.
: SK reports advisory board activity for Pfizer, Incyte/Ariad, Novartis, AOP Pharma, BMS, CTI, Roche, Baxalta, Sanofi; honoraria from Novartis, BMS, Pfizer, Incyte/Ariad, Shire, Roche, AOP Pharma, Janssen; research funding from Novartis Foundation, BMS, Novartis; and other financial disclosures (i.e., travel support) from Alexion, Novartis, BMS, Incyte/Ariad, AOP Pharma, Baxalta, CTI, Pfizer, Sanofi, Celgene, Shire, and Janssen. THB reports consultancy from Pfizer, Novartis, Janssen, Merck, Incyte/Ariad and research funding from Pfizer and Novartis. DG reports advisory board activity for AMGEN, Celgene, and TAKEDA; travel grants for AMGEN, Celgene, and TAKEDA; and was invited speaker for AMGEN, Celgene, BMS, and TAKEDA. The remaining authors declare no conflict of interest.